NMCC - Profile

:::

林亮羽 (Liang-Yu Lin)

Return Appointment First Appointment

Education
Career and Experience
Current Positions：
- - Now, Attending physician, Division of Endocrinology & Metabolism, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
- - Now, Assistant Professor, Department of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan
Experiences：
- - , Visiting scholar, University of California Los Angeles, U.S.A.
Medical Expertise
1. Diabetic vasculopathy, pancreatic neuroendocrine tumor
2. Endocrinology and Diabetes
License

Subspecialty of Endocrinology and Metabolism Taiwan Board of Internal Medicine Certificate Certified Diabetes Educator

通訊作者

Li-Hsin Chang, Ting-Ting Chang, Chia-Huei Chu, Chin-Chou Huang, Liang-Yu Lin. Soluble tumor necrosis factor receptor type 1 is an alternative marker of urinary albumin-creatinine ratio and estimated glomerular filtration rate for predicting the decline of renal function in subjects with type 2 diabetes mellitus. Clinica Chimica Acta. [IF 5.0]

第一加通訊作者

Lin LY, Chang TT, Leu HB, Huang CC, Wu TC, Chou RH, Huang PH, Yin WH, Tseng WK, Wu YW, Lin TH, Yeh HI, Chang KC, Wang JH, Wu CC, *Chen JW. Novel prognostic impact and cell specific role of endocan in patients with coronary artery disease. Clin Res Cardio. 2024 April 30. [IF 5.0]

共同作者

Chang TT, Lin LY, Chen C, Chen JW. CCL4 contributes to aging related angiogenic insufficiency through activating oxidative stress and endothelial inflammation. Angiogenesis. 2024 April 15. [IF:9.8]
Chen C, Lin LY, Wu YW, Chen JW, Chang TT. CXCL5 inhibition improves kidney function by protecting renal tubular epithelial cells in diabetic kidney disease. Clin Immunol. 2024 Sep 24. [IF 4.5]
Chang TT, Li YZ, Mo HW, Chen C, Lin LY, Chang CC, Chen JW. CCL7 is a novel target for endothelial dysfunction and vasculopathy in diabetes mellitus. Science Translational Medicine. 2024 Nov 4. [IF 15.8]